Lunit Unifies Under One Brand, Transforming AI Cancer Detection and Care

Lunit Rebrands Volpara to Form a Unified Cancer Intelligence Initiative

In a significant shift in the landscape of cancer diagnostics and treatment, Lunit, one of the leading AI-centered companies in healthcare, has announced the rebranding of Volpara Health Technologies to operate under the Lunit brand. This strategic move marks an important milestone in Lunit's vision to consolidate its strengths in breast health and AI innovation, creating a more cohesive identity that embodies their commitment to combating cancer through technology.

This rebranding comes on the heels of Lunit's acquisition of Volpara in 2024, which laid the groundwork for merging both entities under a shared mission to improve cancer care via artificial intelligence. The consolidation promotes a broad ecosystem that not only focuses on early detection and risk prediction but also enhances imaging quality and paves the way for data-driven precision medicine. This effort elevates Lunit among only a handful of global AI healthcare firms boasting a wide-ranging portfolio, catering to over 10,000 healthcare providers across more than 65 countries around the world.

Brandon Suh, the CEO of Lunit, expressed enthusiasm regarding the integration. He stated, "By bringing Volpara under the Lunit brand, we're uniting our technologies, teams, and mission to deliver a connected ecosystem that transforms how cancer is detected and treated worldwide." The transition to a unified operation signifies a new era for collaboration and advancement within cancer care—affecting how detection, treatment, and patient engagement are approached across various stages of the cancer journey.

As a part of its evolution, Lunit is reconfiguring its global operational structure. Lunit International, previously known as Volpara Health Technologies, will spearhead business development and customer relations in key markets including the U.S., Oceania, Europe, and Asia. This realignment will allow Lunit's headquarters in Seoul to focus further on advancing research in AI, pushing boundaries in innovation, and developing new products.

Additionally, Lunit has begun transitioning parts of its global sales organization into regional hubs. This strategic realignment will enable the company to enhance its regional growth while simultaneously investing resources into AI research and new product developments, ensuring that its operational focus aligns with current healthcare challenges and innovations.

Alongside these structural changes, Lunit has unveiled a newly designed website (www.lunit.io/en) that reflects its updated digital identity. This site now serves as a centralized hub for accessing their AI solutions, research materials, and corporate resources, reinforcing the unified brand message and its commitment to accessibility.

Suh reiterated the company's commitment, stating, "Our mission remains the same. We aim to make AI the new standard for the entire cancer journey. We want every patient, regardless of geography or resources, to benefit from the same level of precision and insight, ensuring equitable access to life-saving diagnostics worldwide."

Founded in 2013, Lunit's vision is to harness the power of AI in healthcare to seek out and treat cancer more effectively. With clinically validated solutions that span medical imaging, breast health, and biomarker analysis, Lunit empowers earlier detection and informs smarter treatment decisions, ultimately leading to more precise outcomes throughout the continuum of cancer care.

The integration of Volpara into Lunit's operations greatly enhances this mission, allowing the company to offer a rich suite of services from risk prediction and early detection to precision oncology. The company's FDA-cleared Lunit INSIGHT suite and breast health solutions are instrumental in facilitating cancer screening in thousands of medical institutions globally. Meanwhile, the Lunit SCOPE platform is actively utilized in research partnerships with leading pharmaceutical companies, aiding in biomarker development and companion diagnostics.

Having been trusted by medical establishments across over 65 countries, Lunit leverages deep medical expertise combined with evolving datasets to deliver significant improvements and outcomes for patients, practitioners, and researchers alike. Headquartered in Seoul and with offices around the globe, Lunit is committed to leading the battle against cancer and enabling a future where AI plays a crucial role in healthcare. For more information, visit their comprehensive new web platform at lunit.io/en.